Literature DB >> 15504887

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.

Prema Gurumurthy1, Geetha Ramachandran, A K Hemanth Kumar, S Rajasekaran, C Padmapriyadarsini, Soumya Swaminathan, S Bhagavathy, P Venkatesan, L Sekar, A Mahilmaran, N Ravichandran, P Paramesh.   

Abstract

We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504887      PMCID： PMC525439          DOI： 10.1128/AAC.48.11.4473-4475.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Determination of acetylator phenotype based on the ratio of acetylisoniazid to isoniazid in urine following an oral dose of ordinary isoniazid.

Authors:  G Raghupati Sarma; G Kannapirin; A S Narayana; S Radhakrishna; S P Tripathy
Journal:  Indian J Med Res       Date:  1976-01       Impact factor: 2.375

2.  The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.

Authors:  G A Ellard; D R Ellard; B W Allen; D J Girling; A J Nunn; S K Teo; T H Tan; H K Ng; S L Chan
Journal:  Am Rev Respir Dis       Date:  1986-06

3.  Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.

Authors:  G Acocella; A Nonis; G Perna; E Patane; G Gialdroni-Grassi; C Grassi
Journal:  Am Rev Respir Dis       Date:  1988-10

4.  Spectrophotofluorometric assay for isoniazid and acetyl isoniazid in plasma adapted to pediatric studies.

Authors:  W A Olson; P G Dayton; Z H Israili; A W Pruitt
Journal:  Clin Chem       Date:  1977       Impact factor: 8.327

5.  Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.

Authors:  P Gurumurthy; N G Nair; G R Sarma
Journal:  Indian J Med Res       Date:  1980-01       Impact factor: 2.375

6.  Small intestinal injury and parasitic diseases in AIDS.

Authors:  D P Kotler; A Francisco; F Clayton; J V Scholes; J M Orenstein
Journal:  Ann Intern Med       Date:  1990-09-15       Impact factor: 25.391

7.  Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.

Authors:  S H Choudhri; M Hawken; S Gathua; G O Minyiri; W Watkins; J Sahai; D S Sitar; F Y Aoki; R Long
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

8.  Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.

Authors:  J Sahai; K Gallicano; L Swick; S Tailor; G Garber; I Seguin; L Oliveras; S Walker; A Rachlis; D W Cameron
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

9.  Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.

Authors:  Prema Gurumurthy; T N Gayathri; S Bhagavathy; P Venkatesan
Journal:  Indian J Exp Biol       Date:  2004-01       Impact factor: 0.818

10.  Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.

Authors:  Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; P Venkatesan; L Sekar; S Kumar; O R Krishnarajasekhar; P Paramesh
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079
View more
  51 in total

1.  Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis.

Authors:  João Bento; Raquel Duarte; Maria Céu Brito; Sónia Leite; Maria Rosário Lobato; Maria do Carmo Caldeira; Aurora Carvalho
Journal:  BMJ Case Rep       Date:  2010-09-29

2.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 5.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

Review 6.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

7.  The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Authors:  Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

8.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; P K Bhavani; T Kannan; S Ramesh Kumar; N Poorana Gangadevi; V V Banurekha; L Sekar; N Ravichandran; G Mathevan; G N Sanjeeva; Rajeshwar Dayal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.

Authors:  A K Hemanth Kumar; Geetha Ramachandran; S Rajasekaran; C Padmapriyadarsini; G Narendran; S Anitha; Sudha Subramanyam; V Kumaraswami; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2009-10       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.